Goldman Sachs, TCGX Lead $152 Million Investment Round in Swiss Biotech Vaderis
By Adria Calatayud
Swiss biotech company Vaderis Therapeutics said it raised $152 million in a funding round jointly led by Goldman Sachs Alternatives' life-sciences arm and healthcare investor TCG Crossover that will help it start a late-stage study for its lead drug.
Omega Funds, EQT Life Sciences, Perceptive Advisors and Kalehua Capital also participated in the round, alongside existing investors Medicxi and Droia, Vaderis said Tuesday.
The company said the new funding should cover its capital needs through the potential U.S. regulatory approval of its lead product, engasertib, an experimental drug for a rare genetic vascular disorder called hereditary hemorrhagic telangiectasia.
Vaderis is starting a phase 3 trial of engasertib, which showed improvements across multiple measures of the disease in patients with HHT in earlier studies, it said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
August 11, 2026 07:49 ET (11:49 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States